Gilead Sciences
GILD
1,493 hedge funds and large institutions have $66.4B invested in Gilead Sciences in 2019 Q1 according to their latest regulatory filings, with 119 funds opening new positions, 602 increasing their positions, 606 reducing their positions, and 108 closing their positions.
10% more first-time investments, than exits
New positions opened: 119 | Existing positions closed: 108
4% more capital invested
Capital invested by funds: $64.1B → $66.4B (+$2.25B)
0.79% more ownership
Funds ownership: 79.3% → 80.09% (+0.79%)
0% less funds holding
Funds holding: 1,498 → 1,493 (-5)
1% less repeat investments, than reductions
Existing positions increased: 602 | Existing positions reduced: 606
12% less funds holding in top 10
Funds holding in top 10: 50 → 44 (-6)
23% less call options, than puts
Call options by funds: $835M | Put options by funds: $1.09B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$375M |
| 2 |
D.E. Shaw & Co
New York
|
+$267M |
| 3 |
Two Sigma Advisers
New York
|
+$186M |
| 4 |
Renaissance Technologies
New York
|
+$181M |
| 5 |
State Street
Boston,
Massachusetts
|
+$168M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
-$696M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$379M |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
-$187M |
| 4 |
APG Asset Management
Amsterdam,
Netherlands
|
-$174M |
| 5 |
O
OppenheimerFunds
New York
|
-$166M |
GILD Hedge Fund Activity: Q1 2019 in Review
1,493 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q1 2019, worth a combined $66.4B — up 3.5% from $64.1B a quarter earlier.
Buyers outnumbered sellers: 119 funds opened new GILD positions and 108 closed out — a net gain of 11 holders — while 602 added to existing stakes and 606 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $375M. The largest seller was Temasek Holdings, exiting entirely with an estimated $696M sold.
- 1,493 institutional investors held Gilead Sciences (GILD) as of Q1 2019, down from 1,498 in Q4 2018.
- Funds reported $66.4B of Gilead Sciences stock for Q1 2019, up 3.5% quarter-over-quarter.
- 119 funds opened new Gilead Sciences positions in Q1 2019 and 108 closed out, a net change of +11 holders.
- The largest Gilead Sciences buyer in Q1 2019 was Capital Research Global Investors, an estimated $375M added.
- The largest Gilead Sciences seller in Q1 2019 was Temasek Holdings, an estimated $696M sold.
Based on aggregated 13F filings for Q1 2019.